The updated KD025-208 data showed continued improvement, with the Overall Response Rate (ORR) increasing to 65% across the modified intent to treat (mITT) population. KD025 continues to be well tolerated and approximately one-quarter of patients remain on KD025 for longer than a year and a half.
Earlier this month, Kadmon announced that the primary endpoint was met in the planned interim analysis of ROCKstar (KD025-213), the fully enrolled pivotal trial of KD025 in cGVHD patients who had received at least two prior lines of systemic therapy. The study showed clinically and statistically significant ORRs of 64% and 67% across the two dose groups. Additional data from the ROCKstar study are expected in Q1 2020.
In addition, results from an analysis supported by Kadmon that modeled
Details of the presentations are as follows:
KD025-208 Oral Presentation
Title: KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)
Session Title: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstruction: Mechanisms of and Therapies for cGVHD
Session Date and Time:
Abstract #: 872
cGVHD Epidemiology Poster
Title: Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation: A
Session Title: 901.
Session Date and Time:
Abstract #: 2109
Kadmon is a biopharmaceutical company developing innovative products for significant unmet medical needs. Our product pipeline is focused on inflammatory and fibrotic diseases as well as immuno-oncology.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the anticipated use of proceeds of the Offering and the closing of the Offering. Such statements may be preceded by the words "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors also include, but are not limited to, (i) the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; (ii) our ability to advance product candidates into, and successfully complete, clinical trials; (iii) our reliance on the success of our product candidates; (iv) the timing or likelihood of regulatory filings and approvals; (v) our ability to expand our sales and marketing capabilities; (vi) the commercialization of our product candidates, if approved; (vii) the pricing and reimbursement of our product candidates, if approved; (viii) the implementation of our business model, strategic plans for our business, product candidates and technology; (ix) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (x) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xi) costs associated with defending intellectual property infringement, product liability and other claims; (xii) regulatory developments in